pH-triggered microparticles for peptide vaccination

Journal of Immunology

Volumn 173, Issue 4, 2004, Pages 2578-2585

  Haining, W Nicholas ^a   Anderson, Daniel G ^b   Little, Steven R ^b   Von Berwelt Baildon, Michael S ^c   Cardoso, Angelo A ^d   Alves, Pedro ^e   Kosmatopoulos, Kostas ^e   Nadler, Lee M ^d   Langer, Robert ^b   Kohane, Daniel S ^f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DIPALMITOYLPHOSPHATIDYLCHOLINE; EPITOPE; EUDRAGIT; EUDRAGIT E 100; IMMUNOLOGICAL ADJUVANT; INFLUENZA A MATRIX PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; POLYMETHACRYLIC ACID; PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; NONHUMAN; PARTICLE SIZE; PH; PH TRIGGERED MICROPARTICLE; PHAGOCYTOSIS; PHAGOSOME; PRIORITY JOURNAL; PROTEIN TRANSPORT; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; VACCINATION;

EID: 4043062872     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.4.2578     Document Type: Article

References (47)

1. Raychaudhuri, S., and K. L. Rock. 1998. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16:1025.
2. Gett, A. V., F. Sallusto, A. Lanzavecchia, and J. Geginat. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4:355.
3. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163:3735.
4. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2:415.
5. + T cells. J. Immunol. 170:1822.
6. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
7. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:47.
8. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 90:4942.
9. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243.
10. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158:2723.
11. Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell. Biol. 1:362.
12. Guermonprez, P., L. Saveanu, M. Kleijmeer, J. Davoust, P. Van Endert, and S. Amigorena. 2003. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425:397.
13. Houde, M., S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M. F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature 425:402.
14. Hanes, J., J. L. Cleland, and R. Langer. 1997. New advances in microsphere-based single-dose vaccines. Adv. Drug Delivery Rev. 28:97.
15. Nixon, D. F., C. Hioe, P. D. Chen, Z. Bian, P. Kuebler, M. L. Li, H. Qiu, X. M. Li, M. Singh, J. Richardson, et al. 1996. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 14:1523.
16. + Th1 cells. Vaccine 13:1741.
17. Kohane, D. S., M. Lipp, R. Kinney, D. Anthony, N. Lotan, and R. Langer. 2002. Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium. J. Biomed. Mater. Res. 59:450.
18. Lynn, D. M., M. M. Amiji, and R. Langer. 2001. pH-responsive polymer microspheres: rapid release of encapsulated material within the range of intracellular pH. Angew. Chem. Int. Ed. 40:1707.
19. Kohane, D. S., D. G. Anderson, C. Yu, and R. Langer. 2003. pH-triggered release of macromolecules from spray-dried polymethacrylate microparticles. Pharm. Res. 20:1533.
20. +-atpases. J. Biol. Chem. 272:29810.
21. Ackerman, A. L., C. Kyritsis, R. Tampe, and P. Cresswell. 2003. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. USA 100:12889.
22. Tabata, Y., and Y. Ikada. 1990. Phagocytosis of polymer microspheres by macrophages. Adv. Polymer. Sci. 94:107.
23. Kohane, D. S., M. Lipp, R. Kinney, N. Lotan, and R. Langer. 2000. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine. Pharm. Res. 17:1243.
24. Von Bergwelt-Baildon, M. S., R. H. Vonderheide, B. Maecker, N. Hirano, K. S. Anderson, M. O. Butler, Z. Xia, W. Y. Zeng, K. W. Wucherpfennig, L. M. Nadler, and J. L. Schultze. 2002. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99:3319.
25. Firat, H., F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, Z. Garcia, M. L. Michel, R. W. Jack, G. Jung, K. Kosmatopoulos, et al. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29:3112.
26. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007.
27. 2m double knockout mice. J. Exp. Med. 185:2043.
28. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154:2733.
29. Wentworth, P. A., A. Vitiello, J. Sidney, E. Keogh, R. W. Chesnut, H. Grey, and A. Sette. 1996. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26:97.
30. Graff-Dubois, S., O. Faure, D. A. Gross, P. Alves, A. Scardino, S. Chouaib, F. A. Lemonnier, and K. Kosmatopoulos. 2002. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 169:575.
31. Francini, G., A. Scardino, K. Kosmatopoulos, F. A. Lemonnier, G. Campoccia, M. Sabatino, D. Pozzessere, R. Petrioli, L. Lozzi, P. Neri, et al. 2002. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 169:4840.
32. Plonquet, A., F. Garcia-Pons, E. Fernandez, C. Philippe, J. Marquet, H. Rouard, M. H. Delfau-Larue, K. Kosmatopoulos, F. Lemonnier, J. P. Farcet, et al. 2003. Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J. Neuroimmunol. 142:93.
33. Alves, P. M., O. Faure, S. Graff-Dubois, D. A. Gross, S. Cornet, S. Chouaib, I. Miconnet, F. A. Lemonnier, and K. Kosmatopoulos. 2003. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201- restricted epitopes. Cancer Res. 63:8476.
34. Faure, O., S. Graff-Dubois, L. Bretaudeau, L. Derre, D. A. Gross, P. M. Alves, S. Cornet, M. T. Duffour, S. Chouaib, I. Miconnet, et al. 2004. Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Int. J. Cancer 108:863.
35. Gross, D. A., S. Graff-Dubois, P. Opolon, S. Cornet, P. Alves, A. Bennaceur-Griscelli, O. Faure, P. Guillaume, H. Firat, S. Chouaib, et al. 2004. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest. 113:425.
36. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815.
37. Thomas, T., S. Balabhadrapathruni, M. A. Gallo, and T. J. Thomas. 2002. Development of polyamine analogs as cancer therapeutic agents. Oncol. Res. 13:123.
38. Nair, S., A. M. Buiting, R. J. Rouse, N. Van Rooijen, L. Huang, and B. T. Rouse. 1995. Role of macrophages and dendfitic cells in primary cytotoxic T lymphocyte responses. Int. Immunol. 7:679.
39. Agrawal, A. K., and C. M. Gupta. 2000. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Delivery Rev. 41:135.
40. + T-cell responses in vivo. Blood 96:3505.
41. Oussoren, C., J. Zuidema, D. J. Crommelin, and G. Storm. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1328:261.
42. Reddy, R., F. Zhou, L. Huang, F. Carbone, M. Bevan, and B. T. Rouse. 1991. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods 141:157.
43. Reddy, R., F. Zhou, S. Nair, L. Huang, and B. T. Rouse. 1992. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1585.
44. + T cells after infection. Nat. Immunol. 3:619.
45. Langenkamp, A., G. Casorati, C. Garavaglia, P. Dellabona, A. Lanzavecchia, and F. Sallusto. 2002. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur. J. Immunol. 32:2046.
46. Thomas, T. T., D. S. Kohane, A. Wang, and R. Langer. 2004. Microparticulate formulations for the controlled release of interleukin-2. J. Pharm. Sci. 93:1100.
47. Ben-Jebria, A., D. Chen, M. L. Eskew, R. Vanbever, R. Langer, and D. A. Edwards. 1999. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm. Res. 16:555.